Who are 153Sm-DOTMP's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Detectnet, Ga 68 Dotatate, Lutathera, Signifor, Somatuline Depot, Sandostatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/153sm-dotmp.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

153Sm-DOTMP — Competitive Intelligence Brief

153Sm-DOTMP (153Sm-DOTMP) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Somatostatin receptor targeting agent. Area: Oncology.

phase 1 Somatostatin receptor targeting agent Somatostatin receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

153Sm-DOTMP (153Sm-DOTMP) — Telix Pharmaceuticals (Innovations) Pty Limited. A radioligand targeting somatostatin receptors

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
153Sm-DOTMP TARGET	153Sm-DOTMP	Telix Pharmaceuticals (Innovations) Pty Limited	phase 1	Somatostatin receptor targeting agent	Somatostatin receptor
Detectnet	copper dotatate Cu-64	Radiomedix	marketed	Radioactive Diagnostic Agent [EPC]	somatostatin receptors, particularly SSTR2	2020-01-01
Ga 68 Dotatate	gallium (68Ga) edotreotide	Uihc Pet Imaging	marketed		Somatostatin receptor type 2	2019-01-01
Lutathera	lutetium (177Lu) oxodotreotide	Aaa Usa Inc	marketed		Somatostatin receptor type 2	2018-01-01
Signifor	PASIREOTIDE	Recordati	marketed	Somatostatin Analog [EPC]	Somatostatin receptor type 5	2012-01-01
Somatuline Depot	LANREOTIDE	Ipsen Pharma	marketed	Somatostatin Analog	Somatostatin receptor type 2	2007-01-01
Sandostatin	OCTREOTIDE	Novartis	marketed	Somatostatin Analog	Somatostatin receptor type 2	1988-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2032-08-23 — Detectnet · 10383961 · US
2032-08-23 — Detectnet · 10159759 · US
2032-08-23 — Detectnet · 11160888 · US
2038-07-25 — Lutathera · 10596278 · US
2038-07-25 — Lutathera · 10596276 · US

Sponsor landscape (Somatostatin receptor targeting agent class)

Telix Pharmaceuticals (Innovations) Pty Limited · 3 drugs in this class
Curasight · 1 drug in this class
Molecular Targeting Technologies, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 153Sm-DOTMP — Competitive Intelligence Brief. https://druglandscape.com/ci/153sm-dotmp. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab